Rucaparib Clinical Trials (2026): 62 Studies for Ovarian Cancer & Fallopian Tube Cancer
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
62 Rucaparib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 37 indications (including Ovarian Cancer & Fallopian Tube Cancer) and 12,968 total planned enrollment. 8 Phase 3 Rucaparib trials and 29 Phase 2 are listed. 2 Rucaparib clinical trials are actively recruiting at 8 U.S. sites across 6 states. Most recent activity: NCT03522246 (Dec 2030).
Where to Participate: All Rucaparib Trial Sites in the U.S. (8 sites across 6 states)
Every actively recruiting Rucaparibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| KY | University of Louisville-James Graham Brown Cancer Center | Louisville40202 | NCT03899155 | Map |
| MA | Dana_Farber Cancer Institute (DFCI) | Boston02215 | NCT03899155 | Map |
| NY | Roswell Park Cancer Institute | Buffalo14263 | NCT03899155 | Map |
| NY | NYU Langone Hematology Oncology Associates-Mineola | Mineola11501 | NCT03899155 | Map |
| OH | Oncology Hematology Care | Cincinnati45242 | NCT03899155 | Map |
| OH | The Ohio University | Columbus43210 | NCT03899155 | Map |
| PA | Lancaster General Health | Lancaster17601 | NCT03899155 | Map |
| TN | Tennesse Oncology | Nashville37203 | NCT03899155 | Map |
Rucaparib clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | terminated | withdrawn | unknown | Total |
|---|---|---|---|---|---|---|---|
| Early P1 | 1 | 1 | |||||
| P1 | 11 | 11 | |||||
| P1/P2 | 1 | 2 | 5 | 3 | 11 | ||
| P2 | 2 | 3 | 15 | 7 | 1 | 1 | 29 |
| P3 | 3 | 5 | 8 | ||||
| N/A | 2 | 2 |
Recruiting Rucaparib clinical trials (2)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT03899155 | Pan Tumor Rollover Study | P2 | Cancer | 1,500 | Aug 2019 |
| NCT02925234 | DRUPThe Drug Rediscovery Protocol (DRUP Trial) | P2 | Cancer | 1,550 | Aug 2016 |
Rucaparib clinical trials by indication
Ovarian Cancer (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04227522 | MAMOC | P3 | completed | Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients |
| NCT04826198 | REVOCAN | P1/P2 | terminated | Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months |
| NCT02855944 | ARIEL4 | P3 | completed | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients |
| NCT01968213 | ARIEL3 | P3 | completed | Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3) |
| NCT03992131 | SEASTAR | P1/P2 | terminated | A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) |
| NCT01891344 | ARIEL2 | P2 | completed | A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) |
| NCT01482715 | — | P1/P2 | completed | A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II) |
Cancer (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03899155 | — | P2 | recruiting | Pan Tumor Rollover Study |
| NCT03768063 | IMbrella B | P3 | active not recruiting | A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study |
| NCT02925234 | DRUP | P2 | recruiting | The Drug Rediscovery Protocol (DRUP Trial) |
| NCT04774406 | — | N/A | completed | Arterial Hypertension Related to PARP Inhibitors (ArteRIB) |
Breast Cancer (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03542175 | — | P1 | completed | A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy |
| NCT03840200 | — | P1 | completed | A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer. |
| NCT03911453 | — | Early P1 | completed | Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors |
| NCT01074970 | — | P2 | completed | PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations |
Epithelial Ovarian Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03522246 | ATHENA | P3 | active not recruiting | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy |
| NCT04539327 | RAP | N/A | completed | Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study |
| NCT03824704 | ARIES | P2 | terminated | A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) |
Solid Tumor (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04276376 | ARIANES | P2 | terminated | Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors |
| NCT04171700 | LODESTAR | P2 | terminated | A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes |
| NCT02986100 | AME | P1 | completed | Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib |
Metastatic Castration Resistant Prostate Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02975934 | TRITON3 | P3 | completed | A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency |
| NCT04179396 | RAMP | P1 | completed | Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP) |
| NCT02952534 | TRITON2 | P2 | completed | A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency |
Prostate Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03338790 | CheckMate 9KD | P2 | completed | An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer |
| NCT03533946 | ROAR | P2 | terminated | Rucaparib in Nonmetastatic prOstAte With BRCAness |
| NCT03572478 | — | P1/P2 | terminated | Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer |
Neoplasms (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03954366 | — | P1 | completed | Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives |
| NCT03521037 | — | P1 | completed | Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor |
| NCT02740712 | DDI | P1 | completed | Pharmacokinetic Drug-Drug Interaction Study of Rucaparib |
Small Cell Lung Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04209595 | — | P1/P2 | completed | PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers |
| NCT03958045 | — | P2 | completed | Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma |
Cervical Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03476798 | Clovis-001 | P2 | completed | Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium |
| NCT03795272 | MaRuC | P2 | withdrawn | Rucaparib Maintenance Therapy in Advanced Cervical Cancer |
Pancreatic Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03140670 | — | P2 | terminated | Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy |
| NCT02042378 | — | P2 | completed | A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation |
Castration-Resistant Prostate Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04455750 | CASPAR | P3 | active not recruiting | A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy |
Metastatic Castration-Resistant Prostate Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04676334 | CATCH-R | P3 | completed | CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib |
Advanced (Stage IIIB-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03462212 | MITO25 | P1/P2 | unknown | Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination |
Leiomyosarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04624178 | — | P2 | active not recruiting | A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma |
Metastatic Castration-resistant Prostate Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04253262 | — | P1/P2 | active not recruiting | A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer |
Esophagus Cancer, Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03995017 | RiME | P1/P2 | unknown | Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma |
Endometrial Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03694262 | EndoBARR | P2 | completed | The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) |
Deleterious BRCA1 Gene Mutation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03845296 | — | P2 | completed | Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) |
Biliary Tract Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03639935 | — | P2 | completed | Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy |
Metastatic Endometrial Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03617679 | — | P2 | completed | Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer |
Mesothelioma, Malignant (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03654833 | MiST | P2 | unknown | Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma |
Stage IV Non-small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03559049 | — | P1/P2 | terminated | Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer |
Metastatic Biliary Tract Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03337087 | — | P1/P2 | unknown | Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer |
Prostate Cancer Metastatic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03413995 | TRIUMPH | P2 | completed | Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations |
ATM Gene Mutation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03442556 | — | P2 | terminated | Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency |
BRCA1 Gene Mutation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03552471 | — | P1 | completed | Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
Bladder Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03397394 | ATLAS | P2 | terminated | Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma |
Advanced Solid Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03499444 | — | P1 | completed | A Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor |
Solid Tumor, Unspecified, Adult (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03318445 | — | P1 | completed | Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair |
Gynecologic Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03101280 | — | P1 | completed | A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer |
Advanced Gastric Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02935634 | FRACTION-GC | P2 | completed | A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer |
Peritoneal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02873962 | — | P2 | active not recruiting | A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib |
Solid Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02711137 | — | P1/P2 | terminated | Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies |
Metastatic Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02505048 | RUBY | P2 | completed | A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature |
Adenocarcinoma of the Oesophagus (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02678182 | PLATFORM | P2 | active not recruiting | Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial |
brca1 Mutation Carrier (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00664781 | — | P2 | completed | Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer |
Rucaparib pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| ATHENA | NCT03522246 | P3 | active not recruiting | Epithelial Ovarian Cancer | 1,097 | PMID 35658487 |
| IMbrella B | NCT03768063 | P3 | active not recruiting | Cancer | 1,000 | — |
| CASPAR | NCT04455750 | P3 | active not recruiting | Castration-Resistant Prostate Carcinoma | 61 | — |
| TRITON3 | NCT02975934 | P3 | completed | Metastatic Castration Resistant Prostate Cancer | 405 | PMID 36795891 |
| MAMOC | NCT04227522 | P3 | completed | Ovarian Cancer | 42 | PMID 40382284 |
| CATCH-R | NCT04676334 | P3 | completed | Metastatic Castration-Resistant Prostate Cancer | 34 | — |
| ARIEL4 | NCT02855944 | P3 | completed | Ovarian Cancer | 349 | PMID 39914419 |
| ARIEL3 | NCT01968213 | P3 | completed | Ovarian Cancer | 564 | PMID 37262961 |
| DRUP | NCT02925234 | P2 | recruiting | Cancer | 1,550 | PMID 37424386 |
| PLATFORM | NCT02678182 | P2 | active not recruiting | Adenocarcinoma of the Oesophagus | 494 | PMID 35623069 |
| EndoBARR | NCT03694262 | P2 | completed | Endometrial Cancer | 30 | PMID 28403786 |
| CheckMate 9KD | NCT03338790 | P2 | completed | Prostate Cancer | 292 | PMID 35977756 |
| TRIUMPH | NCT03413995 | P2 | completed | Prostate Cancer Metastatic | 12 | PMID 33084183 |
| ARIANES | NCT04276376 | P2 | terminated | Solid Tumor | 130 | — |
| MiST | NCT03654833 | P2 | unknown | Mesothelioma, Malignant | 186 | PMID 35157829 |
| Clovis-001 | NCT03476798 | P2 | completed | Cervical Cancer | 49 | — |
| ROAR | NCT03533946 | P2 | terminated | Prostate Cancer | 7 | PMID 38452035 |
| LODESTAR | NCT04171700 | P2 | terminated | Solid Tumor | 83 | PMID 40632975 |
| FRACTION-GC | NCT02935634 | P2 | completed | Advanced Gastric Cancer | 190 | — |
| ARIEL2 | NCT01891344 | P2 | completed | Ovarian Cancer | 491 | PMID 35170751 |
| TRITON2 | NCT02952534 | P2 | completed | Metastatic Castration Resistant Prostate Cancer | 277 | PMID 32203306 |
| ARIES | NCT03824704 | P2 | terminated | Epithelial Ovarian Cancer | 1 | — |
| ATLAS | NCT03397394 | P2 | terminated | Bladder Cancer | 97 | PMID 34030643 |
| RUBY | NCT02505048 | P2 | completed | Metastatic Breast Cancer | 41 | — |
| MaRuC | NCT03795272 | P2 | withdrawn | Cervical Cancer | 0 | — |
Terminated and withdrawn Rucaparib trials (13)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT03442556terminatedDocetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency
- NCT03559049terminatedRucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer
- NCT04826198terminatedSafety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months
- NCT04276376terminatedEfficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors
- NCT03140670terminatedMaintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy
- NCT03533946terminatedRucaparib in Nonmetastatic prOstAte With BRCAness
- NCT04171700terminatedA Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes
- NCT03992131terminatedA Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)
- NCT03572478terminatedRucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer
- NCT03824704terminatedA Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
- NCT03397394terminatedRucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
- NCT03795272withdrawnRucaparib Maintenance Therapy in Advanced Cervical Cancer
- NCT02711137terminatedOpen-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
All Rucaparib trials (62)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT03522246 | ATHENA | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy | P3 | active not recruiting | 1,097 | pharmaand GmbH | May 2018 |
| NCT03899155 | Pan Tumor Rollover Study | P2 | recruiting | 1,500 | Bristol-Myers Squibb | Aug 2019 | |
| NCT03768063 | IMbrella B | A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study | P3 | active not recruiting | 1,000 | Hoffmann-La Roche | Feb 2019 |
| NCT02925234 | DRUP | The Drug Rediscovery Protocol (DRUP Trial) | P2 | recruiting | 1,550 | The Netherlands Cancer Institute | Aug 2016 |
| NCT04455750 | CASPAR | A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy | P3 | active not recruiting | 61 | Alliance for Clinical Trials in Oncology | Oct 2021 |
| NCT02678182 | PLATFORM | Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial | P2 | active not recruiting | 494 | Royal Marsden NHS Foundation Trust | Feb 2015 |
| NCT04253262 | A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer | P1/P2 | active not recruiting | 13 | Brown University | Apr 2020 | |
| NCT02873962 | A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib | P2 | active not recruiting | 72 | Dana-Farber Cancer Institute | Nov 2016 | |
| NCT04624178 | A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma | P2 | active not recruiting | 20 | Memorial Sloan Kettering Cancer Center | Nov 2020 | |
| NCT03694262 | EndoBARR | The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) | P2 | completed | 30 | Medical College of Wisconsin | Jul 2019 |
| NCT03617679 | Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer | P2 | completed | 79 | University of Colorado, Denver | Mar 2019 | |
| NCT03542175 | A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy | P1 | completed | 31 | Memorial Sloan Kettering Cancer Center | May 2018 | |
| NCT03337087 | Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer | P1/P2 | unknown | 18 | Academic and Community Cancer Research United | Nov 2018 | |
| NCT03442556 | Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency | P2 | terminated | 18 | University of Washington | Aug 2018 | |
| NCT03559049 | Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer | P1/P2 | terminated | 25 | University of Michigan Rogel Cancer Center | Dec 2018 | |
| NCT03462212 | MITO25 | Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination | P1/P2 | unknown | 290 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Mar 2021 |
| NCT04209595 | PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers | P1/P2 | completed | 10 | National Cancer Institute (NCI) | Apr 2020 | |
| NCT03338790 | CheckMate 9KD | An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer | P2 | completed | 292 | Bristol-Myers Squibb | Dec 2017 |
| NCT03995017 | RiME | Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma | P1/P2 | unknown | 34 | University of Kansas Medical Center | Jan 2020 |
| NCT03845296 | Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | P2 | completed | 64 | SWOG Cancer Research Network | Apr 2019 | |
| NCT03413995 | TRIUMPH | Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations | P2 | completed | 12 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Sep 2018 |
| NCT02975934 | TRITON3 | A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency | P3 | completed | 405 | pharmaand GmbH | Jun 2017 |
| NCT04227522 | MAMOC | Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients | P3 | completed | 42 | North Eastern German Society of Gynaecological Oncology | Jun 2020 |
| NCT03639935 | Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy | P2 | completed | 32 | University of Michigan Rogel Cancer Center | Mar 2019 | |
| NCT04826198 | REVOCAN | Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months | P1/P2 | terminated | 13 | Gustave Roussy, Cancer Campus, Grand Paris | Oct 2020 |
| NCT04276376 | ARIANES | Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors | P2 | terminated | 130 | Gustave Roussy, Cancer Campus, Grand Paris | Apr 2019 |
| NCT03654833 | MiST | Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma | P2 | unknown | 186 | University of Leicester | Jan 2019 |
| NCT03476798 | Clovis-001 | Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium | P2 | completed | 49 | University of Oklahoma | Jun 2018 |
| NCT03140670 | Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy | P2 | terminated | 46 | Abramson Cancer Center at Penn Medicine | Sep 2017 | |
| NCT04676334 | CATCH-R | CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib | P3 | completed | 34 | pharmaand GmbH | Mar 2021 |
| NCT04179396 | RAMP | Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP) | P1 | completed | 8 | pharmaand GmbH | Dec 2019 |
| NCT03533946 | ROAR | Rucaparib in Nonmetastatic prOstAte With BRCAness | P2 | terminated | 7 | University of Utah | May 2019 |
| NCT03552471 | Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer | P1 | completed | 25 | Ohio State University Comprehensive Cancer Center | Jul 2018 | |
| NCT03958045 | Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma | P2 | completed | 33 | Zhonglin Hao | Sep 2019 | |
| NCT02855944 | ARIEL4 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | P3 | completed | 349 | pharmaand GmbH | Mar 2017 |
| NCT04774406 | Arterial Hypertension Related to PARP Inhibitors (ArteRIB) | — | completed | 2,336 | University Hospital, Caen | Feb 2021 | |
| NCT04171700 | LODESTAR | A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes | P2 | terminated | 83 | pharmaand GmbH | Jan 2020 |
| NCT01968213 | ARIEL3 | Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3) | P3 | completed | 564 | pharmaand GmbH | Apr 2014 |
| NCT02935634 | FRACTION-GC | A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer | P2 | completed | 190 | Bristol-Myers Squibb | Nov 2016 |
| NCT03992131 | SEASTAR | A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) | P1/P2 | terminated | 25 | pharmaand GmbH | Jun 2019 |
| NCT03499444 | A Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor | P1 | completed | 29 | pharmaand GmbH | Feb 2018 | |
| NCT03840200 | A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer. | P1 | completed | 51 | Hoffmann-La Roche | Jun 2019 | |
| NCT01891344 | ARIEL2 | A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) | P2 | completed | 491 | pharmaand GmbH | Oct 2013 |
| NCT04539327 | RAP | Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study | — | completed | 51 | Grupo Español de Investigación en Cáncer de Ovario | Jul 2020 |
| NCT02952534 | TRITON2 | A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency | P2 | completed | 277 | pharmaand GmbH | Feb 2017 |
| NCT03911453 | Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors | Early P1 | completed | 20 | University of Arizona | Apr 2019 | |
| NCT03954366 | Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives | P1 | completed | 36 | pharmaand GmbH | Apr 2019 | |
| NCT03318445 | Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair | P1 | completed | 22 | Pamela Munster | Jan 2018 | |
| NCT03521037 | Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor | P1 | completed | 16 | pharmaand GmbH | Feb 2018 | |
| NCT03572478 | Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer | P1/P2 | terminated | 12 | University of Chicago | Aug 2018 | |
| NCT03824704 | ARIES | A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) | P2 | terminated | 1 | pharmaand GmbH | Aug 2019 |
| NCT03101280 | A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer | P1 | completed | 29 | Hoffmann-La Roche | Apr 2017 | |
| NCT03397394 | ATLAS | Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma | P2 | terminated | 97 | pharmaand GmbH | Jun 2018 |
| NCT02505048 | RUBY | A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature | P2 | completed | 41 | UNICANCER | Mar 2016 |
| NCT03795272 | MaRuC | Rucaparib Maintenance Therapy in Advanced Cervical Cancer | P2 | withdrawn | 0 | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | Oct 2019 |
| NCT02740712 | DDI | Pharmacokinetic Drug-Drug Interaction Study of Rucaparib | P1 | completed | 17 | pharmaand GmbH | Apr 2016 |
| NCT01482715 | A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II) | P1/P2 | completed | 136 | pharmaand GmbH | Nov 2011 | |
| NCT02711137 | Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies | P1/P2 | terminated | 137 | Incyte Corporation | May 2016 | |
| NCT01074970 | PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations | P2 | completed | 135 | Hoosier Cancer Research Network | Feb 2010 | |
| NCT02986100 | AME | Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib | P1 | completed | 6 | pharmaand GmbH | Nov 2016 |
| NCT02042378 | A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation | P2 | completed | 19 | pharmaand GmbH | Apr 2014 | |
| NCT00664781 | Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer | P2 | completed | 78 | Cancer Research UK | Dec 2007 |
Rucaparib clinical trials: frequently asked questions
- How many Rucaparib clinical trials are there?
- 62 Rucaparib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 2 are actively recruiting participants. 36 are marked completed.
- Are Rucaparib clinical trials recruiting in 2026?
- Yes — 2 Rucaparib trials are actively recruiting in 2026, with 8 U.S. sites across 6 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Rucaparib being studied for?
- Rucaparib is being studied for Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Epithelial Ovarian Cancer, Breast Cancer and 100 more. The trials are grouped by indication on this page.
- What phase is Rucaparib in?
- Rucaparib clinical trials span 8 Phase 3, 29 Phase 2, 11 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Rucaparib clinical trials?
- The lead sponsor across the most Rucaparib trials is pharmaand GmbH, with 36 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Rucaparibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: